Related Experiment Video
Updated: Jun 27, 2026
04:14
Incorporation of a Survivable Liver Biopsy Procedure in Mice to Assess Non-alcoholic Steatohepatitis (NASH) Resolution
Published on: April 16, 2019
Semaglutide Selectively Improves Metabolic and Cognitive Function in 5xFAD Mice.
Lucy Shahabian1,2, Demos Kynigopoulos1,2, Revekka Papacharalambous1
1Neuropathology Department, Cyprus Institute of Neurology and Genetics, 2371 Nicosia, Cyprus.
International Journal of Molecular Sciences
|June 26, 2026
Summary
Semaglutide (SMGL) improved metabolic dysfunction and Alzheimer's disease (AD) pathology in mice with metabolic challenges. This suggests targeting metabolic issues may offer a new strategy for AD neuroprotection.
Area of Science:
- Neuroscience
- Metabolic Research
- Pharmacology
Background:
- Alzheimer's disease (AD) and metabolic syndrome share risk factors like insulin resistance and inflammation.
- Metabolic dysfunction often precedes cognitive decline in AD, highlighting the need for early interventions.
Purpose of the Study:
- To investigate the effects of the GLP-1 receptor agonist semaglutide (SMGL) on metabolic impairment and AD pathology.
- To assess SMGL's impact on cognitive function and neuroinflammation in a mouse model of AD.
Main Methods:
- Administered semaglutide (SMGL) to 5xFAD and wild-type mice on regular or high-fat diets for 13 weeks.
- Evaluated metabolic parameters (glucose tolerance, body weight, lipid profiles), AD biomarkers (Aβ levels), neuroinflammation markers, and spatial memory.
Main Results:
- In metabolically stressed AD mice, SMGL improved glucose tolerance, normalized cholesterol, reduced body weight, and decreased amyloid-beta (Aβ) levels.
- SMGL treatment also reduced neuroinflammation markers (Iba1, CD68), enhanced synaptic plasticity markers, and improved spatial memory.
- Minimal metabolic effects were observed in healthy mice, suggesting context-dependent action.
Conclusions:
- Semaglutide (SMGL) acts as a context-specific metabolic and neuroprotective agent, most beneficial under metabolic dysfunction.
- Targeting early metabolic disturbances with agents like SMGL presents a potential therapeutic strategy for attenuating Alzheimer's disease (AD) neurodegeneration.
- Further translational studies are needed to confirm these findings in humans.
